Related Experiment Video
Updated: Nov 22, 2025

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model
Published on: May 26, 2023
Dose estimation for bivalirudin during pediatric cardiopulmonary bypass
Philip Wolstencroft1, Philip Arnold2, Brian J Anderson3
1Department of Paediatric Anaesthesia, Starship Children's Hospital, Auckland, New Zealand.
Insights
Bivalirudin dosing for pediatric cardiopulmonary bypass is now clarified. Higher infusion rates are recommended for children, with specific adjustments for infants and older children, unlike adult regimens.
Area of Science:
- Pharmacology
- Pediatric Surgery
- Cardiovascular Medicine
Background:
- Bivalirudin is an anticoagulant used during cardiopulmonary bypass (CPB).
- Standard adult dosing regimens for bivalirudin during CPB are established.
- Pediatric bivalirudin dosing for CPB remains undetermined, posing a clinical challenge.
Purpose of the Study:
- To establish a practical bivalirudin dosing schedule for pediatric patients undergoing CPB.
- To determine appropriate bivalirudin infusion rates for children based on allometric scaling of adult pharmacokinetic data.
Main Methods:
- Compared published pediatric pharmacokinetic data from cardiac catheterization with adult parameters.
- Utilized allometric scaling to adjust for body size differences between pediatric and adult patients.
- Determined pediatric infusion rates to achieve a target bivalirudin concentration (13 mg/L) and activated clotting time (>400 s).
Main Results:
- Bivalirudin clearance in children decreases with age, necessitating higher infusion rates compared to adults.
- Recommended pediatric infusion rates: 4.5 mg/h/kg for infants (10 kg), 4 mg/h/kg for children (20 kg), and 3.5 mg/h/kg for children (30-40 kg).
- Adult bivalirudin regimens are suggested for children weighing over 50 kg.
Conclusions:
- Pediatric bivalirudin infusion should commence at higher rates than adult doses post-loading.
- Neonatal bivalirudin dosing requires further investigation due to limited pharmacokinetic and pharmacodynamic data.
- The proposed dosing schedule aims to achieve therapeutic anticoagulation during pediatric CPB.
Aim:
A typical adult-based bivalirudin regimen during cardiopulmonary bypass uses a loading dose of 1 mg kg-1 and a circuit prime (volume L × 13 mg) with a subsequent intravenous infusion 2.5 mg h-1 kg-1 . Dose in children remains unknown. We wished to determine a practical bivalirudin dosing schedule for children undergoing surgery with cardiopulmonary bypass.
Methods:
Published pharmacokinetic parameters in children who were anticoagulated for cardiac catheterization using bivalirudin were compared to adult by scaling for size using allometry. An infusion regimen suitable for children was determined using a bivalirudin target concentration (13 mg L-1 ) common in adults for effect during cardiopulmonary bypass. Predicted bivalirudin infusion rates in children were compared to regimens published as case reports.
Results:
Current pediatric bivalirudin infusion rates are based on those used in adults with titration during cardiopulmonary bypass to achieve activated clotting times longer than 400 s. Bivalirudin clearance (mL min-1 kg-1 ) can be estimated in children by scaling adult parameters using allometry. Clearance decreases through childhood and higher infusion rates in children would achieve target concentration rapidly without the need to titrate initial infusion rate. An infusion rate of 4.5 mg h-1 kg-1 in a 10 kg infant, 4 mg h-1 kg-1 in a 20 kg child and 3.5 mg h-1 kg-1 in a child 30-40 kg will target an activated clotting time slower than 400 s. Adult regimens could be used in those children heavier than 50 kg.
Conclusion:
Bivalirudin infusion in children should be started after loading dose at rates greater than those used in adults. Dose in neonates remains uncertain because neither pharmacokinetics nor coagulation pharmacodynamics have been adequately characterized.
Related Concept Videos
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Drug Excretion
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

